Want to see AU:MVF full AI Analyst Report?
Top Page
Monash IVF Group Ltd
(Sydney:MVF)
Select Model
Select Model
Rating:56Neutral
Price Target:
AU$0.73
â–˛(5.94% Upside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by weaker recent financial performance (margin compression, higher leverage, and softer free cash flow) and a rich valuation (high P/E). These negatives are partially offset by strong recent price strength versus moving averages and positive MACD, though overbought RSI/Stoch signals temper the technical outlook.
Positive Factors
Integrated fertility care model
MVF combines clinical treatment, laboratory work and diagnostics within a single fertility-care pathway. This integrated model can support patient continuity, capture more services per treatment journey, and reinforce the value of its clinic and specialist infrastructure over the medium term.
Negative Factors
Sharp margin compression
The steep decline in gross and net margins indicates materially weaker earnings conversion from revenue. If margins remain near current levels, MVF may have less capacity to fund expansion, absorb operating volatility, or translate stable patient demand into durable profit growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated fertility care model
MVF combines clinical treatment, laboratory work and diagnostics within a single fertility-care pathway. This integrated model can support patient continuity, capture more services per treatment journey, and reinforce the value of its clinic and specialist infrastructure over the medium term.
Read all positive factors
Monash IVF Group Ltd (MVF) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$278.59M
Dividend Yield3.52%
Average Volume (3M)464.87K
Price to Earnings (P/E)37.7
Beta (1Y)1.16
Revenue Growth-0.90%
EPS Growth-70.25%
CountryAU
Employees892
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.02
Shares Outstanding389,634,830
10 Day Avg. Volume477,791
30 Day Avg. Volume464,865
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)1.13
Price to Sales (P/S)1.05
P/FCF Ratio38.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.78Price Target Upside12.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.05
Revenue Forecast (FY)AU$280.80M
Monash IVF Group Ltd Business Overview & Revenue Model
Company Description
Founded in 2014 and headquartered in Richmond, Australia, Monash IVF Group Limited delivers specialized reproductive assistance and women's imaging services. Its operations span Australia and Malaysia, offering a broad spectrum of care. This inclu...
How the Company Makes Money
MVF primarily makes money by delivering fertility treatment cycles and associated clinical services to patients. The company’s revenue model is largely fee-for-service, with income generated from: (1) clinical fertility procedures and treatment pr...
Monash IVF Group Ltd Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
57
Neutral
Cash Flow
49
Neutral
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 269.46M | 271.92M | 254.96M | 213.59M | 192.29M |
| Gross Profit | 61.93M | 90.31M | 85.50M | 63.41M | 57.22M |
| EBITDA | 44.03M | 66.19M | 10.78M | 48.49M | 43.16M |
| Net Income | 7.42M | 25.01M | -6.53M | 21.84M | 18.41M |
Balance Sheet | |||||
| Total Assets | 512.35M | 492.61M | 508.47M | 421.89M | 387.10M |
| Cash, Cash Equivalents and Short-Term Investments | 8.84M | 9.43M | 11.33M | 8.01M | 7.87M |
| Total Debt | 199.62M | 180.31M | 135.37M | 100.04M | 77.23M |
| Total Liabilities | 258.88M | 242.19M | 261.81M | 146.82M | 117.20M |
| Stockholders Equity | 249.16M | 246.28M | 241.91M | 273.20M | 267.92M |
Cash Flow | |||||
| Free Cash Flow | 7.27M | 468.00K | 31.70M | 10.16M | 19.51M |
| Operating Cash Flow | 30.20M | 12.90M | 52.52M | 37.95M | 31.28M |
| Investing Cash Flow | -23.77M | -17.43M | -38.80M | -40.51M | -15.16M |
| Financing Cash Flow | -6.85M | 2.67M | -10.39M | 1.51M | -17.02M |
Monash IVF Group Ltd Technical Analysis
Positive
0.69
Price Trends
0.74
Negative
0.71
Positive
0.70
Positive
Market Momentum
>-0.01
Positive
46.52
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVF, the sentiment is Positive. The current price of 0.69 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.74, and below the 200-day MA of 0.70, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.52 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MVF.
Monash IVF Group Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | AU$9.26B | 15.27 | 7.20% | 5.74% | 14.40% | 15.11% | |
61 Neutral | AU$61.26M | 27.40 | 52.84% | 9.33% | 18.31% | 18.65% | |
56 Neutral | AU$278.59M | 37.70 | 2.95% | 3.52% | -0.90% | -70.25% | |
54 Neutral | AU$540.91M | 23.62 | 15.80% | 4.45% | -0.90% | -25.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$283.21M | -0.70 | -114.08% | 35.60% | 2.16% | 21.05% |
* Healthcare Sector Average
AU:MVF
Monash IVF Group Ltd
0.73
0.05
7.35%
AU:HLS
Healius Limited
0.42
-0.40
-48.77%
AU:CTE
Cryosite Limited
1.26
0.15
14.09%
AU:SHL
Sonic Healthcare Limited
18.97
-1.58
-7.68%
AU:ACL
Australian Clinical Labs Ltd
2.92
0.31
11.79%
Monash IVF Group Ltd Corporate Events
Monash IVF appoints experienced finance leader as new CFO
Oct 8, 2026
Monash IVF Group has appointed Matt Harrington as its new Chief Financial Officer, with his commencement expected by early January 2027 after he completes current commitments and a transition process. Harrington brings more than two decades of sen...
Monash IVF Sets Key Shareholder Dates for 2026 Dividend and AGM
Sep 24, 2026
Monash IVF Group Limited has outlined key shareholder dates for the remainder of 2026, including the closing time for director nominations at 5pm AEDT on 8 October and the final dividend payment scheduled for 15 October. The company will also rele...
Monash IVF to Release Small Tranche of Escrowed Shares
Sep 3, 2026
Monash IVF Group has announced that 65,273 fully paid ordinary shares currently subject to voluntary escrow will be released on 10 September 2026. The company confirmed that this release does not alter its total issued capital, with 9,423,322 full...
Monash IVF Appoints New Director Effective September 2026
Sep 3, 2026
Monash IVF Group Limited has announced the appointment of Gerd Schenkel as a director, effective 1 September 2026, and lodged an Initial Director’s Interest Notice with the ASX in accordance with listing rule disclosure requirements. The fil...
Monash IVF Issues New Performance Rights Under Employee Incentive Scheme
Sep 3, 2026
Monash IVF Group Limited has notified the market of the issue of 112,921 unquoted performance rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on 21 July 2026 and reflect t...
Monash IVF Discloses Final Director Interest as Broekhuizen Departs Board
Aug 30, 2026
Monash IVF Group Limited has announced a change in its board composition with the cessation of director Neil John Broekhuizen effective 31 August 2026. The disclosure was made under ASX listing rule requirements, reflecting the company’s ong...
Monash IVF Unveils Board Overhaul as Catherine West Named Chair-elect
Aug 30, 2026
Monash IVF Group has announced a major board succession and renewal program, including the appointment of director Catherine West as Chair-elect to succeed long-serving Chair Richard Davis, and the addition of technology and customer experience sp...
Monash IVF lodges ASX governance statement, affirms full compliance
Aug 30, 2026
Monash IVF Group Limited has lodged its corporate governance statement for the financial year ended 30 June 2026 with the ASX, confirming that the document is available on its website and has been approved by the board as at 21 August 2026. The ac...
Monash IVF posts softer FY26 profit but boosts market share and cash flow
Aug 30, 2026
Monash IVF reported FY26 revenue of $269.5 million, down 0.9% year on year, with underlying EBITDA falling 19.5% to $53.4 million and underlying NPAT down 41.2% to $16.1 million, partly due to softer domestic stimulated cycle volumes and cost pres...
Monash IVF Declares Interim Dividend for June Half‑Year
Aug 30, 2026
Monash IVF Group Limited has declared an interim dividend of A$0.013 per ordinary fully paid share for the six‑month period ended 30 June 2026. The distribution applies to its MVF securities, with an ex‑dividend date of 3 September, re...
Monash IVF Profit Slumps as Costs Rise, Dividend Trimmed
Aug 30, 2026
Monash IVF Group reported underlying net profit after tax of $16.1m for the year ended 30 June 2026, undershooting June guidance and marking a 41.2% decline from the prior year, as revenue slipped 0.9% and underlying EBITDA fell 19.5%. Statutory p...
Monash IVF Delays FY2026 Results Release Amid Extended Audit
Aug 23, 2026
Monash IVF Group Limited has delayed the release of its FY2026 financial results, originally scheduled for 24 August 2026, after the audit of its financial statements took longer than expected. Management is working with the company’s audito...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.